{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:18:08Z","timestamp":1787242688398,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The gut microbiota interacts with infectious diseases and affects host immunity. Liver disease is also reportedly associated with changes in the gut microbiota. To elucidate the changes in the gut microbiota before and after hepatitis C virus (HCV) eradication through direct-acting antiviral (DAA) treatment in patients with chronic hepatitis C (CHC), we investigated 42 samples from 14 patients who received DAA therapy for HCV. Fecal samples were obtained before treatment (Pre), when treatment ended (EOT), and 24\u00a0weeks after treatment ended (Post24). The target V3\u20134 region of the 16S rRNA gene from fecal samples was amplified using the Illumina Miseq sequencing platform. The diversity of the gut microbiota did not significantly differ between Pre, EOT, and Post24. Principal coordinates analysis showed that for each patient, the values at Pre, EOT, and Post24 were concentrated within a small area. The linear discriminant analysis of effect size showed that the relative abundances of\n                    <jats:italic>Faecalibacterium<\/jats:italic>\n                    and\n                    <jats:italic>Bacillus<\/jats:italic>\n                    increased at EOT, further increased at Post24, and were significantly increased at Post24 compared to Pre. These suggest that changes in the gut microbiota should be considered as among the various effects observed on living organisms after HCV eradication.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-03009-0","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T06:02:38Z","timestamp":1638856958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Changes in the gut microbiota after hepatitis C virus eradication"],"prefix":"10.1038","volume":"11","author":[{"given":"Takashi","family":"Honda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"3009_CR1","volume-title":"Global Hepatitis Report","author":"WHO","year":"2017","unstructured":"WHO. Global Hepatitis Report (WHO, 2017)."},{"key":"3009_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina, Y. et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58, 1253\u20131262. https:\/\/doi.org\/10.1002\/hep.26442 (2013).","journal-title":"Hepatology"},{"key":"3009_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/jgh.12915","volume":"30","author":"H Toyoda","year":"2015","unstructured":"Toyoda, H. et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 30, 1183\u20131189. https:\/\/doi.org\/10.1111\/jgh.12915 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"3009_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hepr.12393","volume":"45","author":"N Hiramatsu","year":"2015","unstructured":"Hiramatsu, N., Oze, T. & Takehara, T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol. Res. 45, 152\u2013161. https:\/\/doi.org\/10.1111\/hepr.12393 (2015).","journal-title":"Hepatol. Res."},{"key":"3009_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/nu7010017nu7010017","volume":"7","author":"MA Conlon","year":"2014","unstructured":"Conlon, M. A. & Bird, A. R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17\u201344. https:\/\/doi.org\/10.3390\/nu7010017nu7010017 (2014).","journal-title":"Nutrients"},{"key":"3009_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert, J. A. et al. Current understanding of the human microbiome. Nat. Med. 24, 392\u2013400. https:\/\/doi.org\/10.1038\/nm.4517nm.4517 (2018).","journal-title":"Nat. Med."},{"key":"3009_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","volume":"152","author":"RB Sartor","year":"2017","unstructured":"Sartor, R. B. & Wu, G. D. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152, 327\u2013339. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.012 (2017).","journal-title":"Gastroenterology"},{"key":"3009_CR8","doi-asserted-by":"publisher","first-page":"26263","DOI":"10.3390\/ijms161125957","volume":"16","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Lun, C. Y. & Tsui, S. K. Metagenomics: A new way to illustrate the crosstalk between infectious diseases and host microbiome. Int. J. Mol. Sci. 16, 26263\u201326279. https:\/\/doi.org\/10.3390\/ijms161125957 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"3009_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","volume":"146","author":"B Schnabl","year":"2014","unstructured":"Schnabl, B. & Brenner, D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146, 1513\u20131524. https:\/\/doi.org\/10.1053\/j.gastro.2014.01.020 (2014).","journal-title":"Gastroenterology"},{"key":"3009_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0168-8278(95)80424-2","volume":"22","author":"RS Lin","year":"1995","unstructured":"Lin, R. S. et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 22, 165\u2013172. https:\/\/doi.org\/10.1016\/0168-8278(95)80424-2 (1995).","journal-title":"J. Hepatol."},{"key":"3009_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2012.05.012","volume":"16","author":"K Imajo","year":"2012","unstructured":"Imajo, K. et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 16, 44\u201354. https:\/\/doi.org\/10.1016\/j.cmet.2012.05.012 (2012).","journal-title":"Cell Metab."},{"key":"3009_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbrc.2015.12.012","volume":"470","author":"K Achiwa","year":"2016","unstructured":"Achiwa, K. et al. DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochem. Biophys. Res. Commun. 470, 15\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2015.12.012 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3009_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi, A. et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397\u2013411. https:\/\/doi.org\/10.1038\/s41575-018-0011-z (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"3009_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep4.1331","volume":"3","author":"N Ohtani","year":"2019","unstructured":"Ohtani, N. & Kawada, N. Role of the gut-liver axis in liver inflammation, fibrosis, and cancer: A special focus on the gut microbiota relationship. Hepatol. Commun. 3, 456\u2013470. https:\/\/doi.org\/10.1002\/hep4.1331 (2019).","journal-title":"Hepatol. Commun."},{"key":"3009_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/apt.13732","volume":"44","author":"JS Bajaj","year":"2016","unstructured":"Bajaj, J. S. et al. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol. Ther. 44, 638\u2013643. https:\/\/doi.org\/10.1111\/apt.13732 (2016).","journal-title":"Aliment Pharmacol. Ther."},{"key":"3009_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/apt.15004","volume":"48","author":"FR Ponziani","year":"2018","unstructured":"Ponziani, F. R. et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol. Ther. 48, 1301\u20131311. https:\/\/doi.org\/10.1111\/apt.15004 (2018).","journal-title":"Aliment Pharmacol. Ther."},{"key":"3009_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/hep.31700","volume":"74","author":"F Wellh\u00f6ner","year":"2021","unstructured":"Wellh\u00f6ner, F. et al. Eradication of chronic HCV infection: Improvement of dysbiosis only in patients without liver cirrhosis. Hepatology 74, 72\u201382. https:\/\/doi.org\/10.1002\/hep.31700 (2021).","journal-title":"Hepatology"},{"key":"3009_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31784","author":"FR Ponziani","year":"2021","unstructured":"Ponziani, F. R. et al. Letter to the Editor. Restructuring the gut microbiota of cirrhotic patients after HCV eradication: A matter of time?. Hepatology https:\/\/doi.org\/10.1002\/hep.31784 (2021).","journal-title":"Hepatology"},{"key":"3009_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejim.2019.06.005","volume":"67","author":"P Perez-Matute","year":"2019","unstructured":"Perez-Matute, P. et al. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients. Eur. J. Intern. Med. 67, 47\u201358. https:\/\/doi.org\/10.1016\/j.ejim.2019.06.005 (2019).","journal-title":"Eur. J. Intern. Med."},{"key":"3009_CR20","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731\u201316736. https:\/\/doi.org\/10.1073\/pnas.0804812105 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3009_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446\u2013450. https:\/\/doi.org\/10.1038\/nature12721nature12721 (2013).","journal-title":"Nature"},{"key":"3009_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.2606ni.2606","volume":"14","author":"DT Utzschneider","year":"2013","unstructured":"Utzschneider, D. T. et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14, 603\u2013610. https:\/\/doi.org\/10.1038\/ni.2606ni.2606 (2013).","journal-title":"Nat. Immunol."},{"key":"3009_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/hepr.12102","volume":"44","author":"Y Kondo","year":"2014","unstructured":"Kondo, Y. et al. Eradication of hepatitis C virus could improve immunological status and pyoderma gangrenosum-like lesions. Hepatol. Res. 44, 238\u2013245. https:\/\/doi.org\/10.1111\/hepr.12102 (2014).","journal-title":"Hepatol. Res."},{"key":"3009_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-018-0616-y","volume":"562","author":"P Piewngam","year":"2018","unstructured":"Piewngam, P. et al. Pathogen elimination by probiotic Bacillus via signalling interference. Nature 562, 532\u2013537. https:\/\/doi.org\/10.1038\/s41586-018-0616-y (2018).","journal-title":"Nature"},{"key":"3009_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cid\/ciy205","volume":"67","author":"T Inoue","year":"2018","unstructured":"Inoue, T. et al. Gut dysbiosis associated with hepatitis C virus infection. Clin. Infect. Dis. 67, 869\u2013877. https:\/\/doi.org\/10.1093\/cid\/ciy205 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"3009_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3164\/jcbn.19-26","volume":"65","author":"Y Naito","year":"2019","unstructured":"Naito, Y. et al. Gut microbiota differences in elderly subjects between rural city Kyotango and urban city Kyoto: An age-gender-matched study. J. Clin. Biochem. Nutr. 65, 125\u2013131. https:\/\/doi.org\/10.3164\/jcbn.19-26 (2019).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"3009_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/B978-0-12-407863-5.00019-8","volume":"531","author":"JA Navas-Molina","year":"2013","unstructured":"Navas-Molina, J. A. et al. Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 531, 371\u2013444. https:\/\/doi.org\/10.1016\/B978-0-12-407863-5.00019-8 (2013).","journal-title":"Methods Enzymol."},{"key":"3009_CR28","doi-asserted-by":"publisher","first-page":"W180","DOI":"10.1093\/nar\/gkx2953760191","volume":"45","author":"A Dhariwal","year":"2017","unstructured":"Dhariwal, A. et al. MicrobiomeAnalyst: A web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 45, W180\u2013W188. https:\/\/doi.org\/10.1093\/nar\/gkx2953760191 (2017).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03009-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:06:30Z","timestamp":1670072790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03009-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-609634\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23568"}}